Abstract
BackgroundThe combination of multi-parametric MRI to locate and define suspected lesions together with their being targeted by an MRI-guided prostate biopsy has succeeded in increasing the detection rate of clinically significant disease and lowering the detection rate of non-significant prostate cancer. In this work we investigate the urologist’s learning curve of in-bore MRI-guided prostate biopsy which is considered to be a superior biopsy technique.Materials and methodsFollowing Helsinki approval by The Chaim Sheba Medical Center ethics committee in accordance with The Sheba Medical Center institutional guidelines (5366-28-SMC) we retrospectively reviewed 110 IB-MRGpBs performed from 6/2016 to 1/2019 in a single tertiary center. All patients had a prostate multi-parametric MRI finding of at least 1 target lesion (prostate imaging reporting and data system [PI-RADS] score ≥ 3). We analyzed biopsy duration and clinically significant prostate cancer detection of targeted sampling in 2 groups of 55 patients each, once by a urologist highly trained in IB-MRGpBs and again by a urologist untrained in IB-MRGpBs. These two parameters were compared according to operating urologist and chronologic order.ResultsThe patients’ median age was 68 years (interquartile range 62–72). The mean prostate-specific antigen level and prostate size were 8.6 ± 9.1 ng/d and 53 ± 27 cc, respectively. The mean number of target lesions was 1.47 ± 0.6. Baseline parameters did not differ significantly between the 2 urologists’ cohorts. Overall detection rates of clinically significant prostate cancer were 19%, 55%, and 69% for PI-RADS 3, 4 and 5, respectively. Clinically significant cancer detection rates did not differ significantly along the timeline or between the 2 urologists. The average duration of IB-MRGpB targeted sampling was 28 ± 15.8 min, correlating with the number of target lesions (p < 0.0001), and independent of the urologist’s expertise. Eighteen cases defined the cutoff for the procedure duration learning curve (p < 0.05).ConclusionsOur data suggest a very short learning curve for IB-MRGpB-targeted sampling duration, and that clinically significant cancer detection rates are not influenced by the learning curve of this technique.
Highlights
Magnetic resonance-guided prostate biopsy (MRGpB) is considered superior to transrectal ultrasound (TRUS)guided biopsy, and multi-parametric magnetic resonance imaging is regarded as a leading tool in diagnosing clinically significant prostate cancer [1,2,3]
Our data suggest a very short learning curve for IB-MRGpB-targeted sampling duration, and that clinically significant cancer detection rates are not influenced by the learning curve of this technique
The combination of multi-parametric magnetic resonance imaging (mpMRI) to locate and define suspected lesions together with their being targeted by Rosenzweig et al BMC Urology (2021) 21:169 an MRI-guided prostate biopsy (MRGpB) has succeeded in increasing the detection rate of clinically significant disease and lowering the detection rate of non-significant prostate cancer [1]
Summary
Magnetic resonance-guided prostate biopsy (MRGpB) is considered superior to transrectal ultrasound (TRUS)guided biopsy, and multi-parametric magnetic resonance imaging (mpMRI) is regarded as a leading tool in diagnosing clinically significant prostate cancer [1,2,3]. The combination of mpMRI to locate and define suspected lesions together with their being targeted by Rosenzweig et al BMC Urology (2021) 21:169 an MRI-guided prostate biopsy (MRGpB) has succeeded in increasing the detection rate of clinically significant disease and lowering the detection rate of non-significant prostate cancer [1]. In the “inbore” approach, following an initial diagnostic mpMRI, the patient undergoes a biopsy within the bore of the magnet at a later date [4, 5] These high-end technologies incorporate multidisciplinary efforts, and may suggest a long learning curve and possible slow adaptation of biopsy techniques whose applications are limited by the number of trained personnel. The combination of multi-parametric MRI to locate and define suspected lesions together with their being targeted by an MRI-guided prostate biopsy has succeeded in increasing the detection rate of clinically significant disease and lowering the detection rate of non-significant prostate cancer. In this work we investigate the urologist’s learning curve of in-bore MRI-guided prostate biopsy which is considered to be a superior biopsy technique
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.